BioInvent and Resistentia have reached a settlement

PRESS RELEASE 12 DECEMBER 2002 BioInvent and Resistentia have reached a settlement Lund, Sweden: BioInvent International AB (SAX:BINV) and Resistentia Pharmaceuticals AB have reached a settlement and thereby avoided a continued and lengthy arbitration process that concerned BioInvent's cell line- and process development of an allergy vaccine on behalf of Resistantia (see earlier press release 2001-12-20). In the settlement neither party assumes any legal liability. The terms of the settlement are confidential. In a joint statement Marcus Bosson, CEO Resistentia, and Svein Mathisen, CEO BioInvent, explain that the parties have chosen to settle the matter in order to focus their resources on their respective business activities. -- END - For more information please contact BioInvent International AB Buchanan Communications Svein Mathisen Nicola How President and CEO Tel. +44 20 7466 5000 Tel: +46 46 286 85 67 Mobile: +44 708 97 82 13 E-mail: svein.mathisen@bioinvent.com Resistentia Pharmaceuticals AB Marcus Bosson President Tel: +46 18 65 39 01 Mobile: +46 70 693 82 81 Notes to Editors: BioInvent International AB, listed on the O-list of the Swedish Exchange, is a biotechnology company devoted to providing state-of-the- art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeR(TM). This is a collection of more than ten billion functional antibody genes that are ready to be screened against desired antigens. n-CoDeR(TM) has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeR(TM) through collaborative research and development programs. BioInvent's capabilities in large-scale contract manufacturing of protein-based drugs through a state-of-the-art cGMP-certified facility further underpin its competitiveness in the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified manufacturing facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total of 130 people. For further information, see www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT01080/wkr0001.doc http://www.waymaker.net/bitonline/2003/09/25/20030925BIT01080/wkr0002.pdf